Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The standard treatment for patients with locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT), but surgical resection following induction CRT can extend overall survival in a select population. However, patients who survive longer are at risk of developing a second primary cancer (SPC). This is the first report to determine the incidence of SPC in survivors with LA-NSCLC after trimodal therapy. Between October 1997 and October 2013, 112 Stage III NSCLC patients underwent trimodal therapy in our hospital. The 5-year overall survival rate was 71.8%. SPC developed in 10 of the 112 patients 0.60-15.0 (median 5.49) years after initiating CRT. The observed incidence of SPC was 1.8 per 100 patient-years. Although trimodal therapy can prolong patient survival, the estimated incidence of SPC does not increase. A large prospective study with a longer follow-up time is required to determine the effects of trimodal therapy, including the development of SPC.

Original languageEnglish
Pages (from-to)287-290
Number of pages4
JournalJapanese Journal of Clinical Oncology
Volume48
Issue number3
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Second Primary Neoplasms
Non-Small Cell Lung Carcinoma
Survivors
Chemoradiotherapy
Incidence
Therapeutics
Survival
Survival Rate
Prospective Studies
Population

Keywords

  • Cancer survivor
  • Chemoradiotherapy
  • Non-small-cell lung cancer
  • Second primary cancer
  • Surgical resection

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

@article{3d707fe986d949baa3c0bebc9ad15216,
title = "Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery",
abstract = "The standard treatment for patients with locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT), but surgical resection following induction CRT can extend overall survival in a select population. However, patients who survive longer are at risk of developing a second primary cancer (SPC). This is the first report to determine the incidence of SPC in survivors with LA-NSCLC after trimodal therapy. Between October 1997 and October 2013, 112 Stage III NSCLC patients underwent trimodal therapy in our hospital. The 5-year overall survival rate was 71.8{\%}. SPC developed in 10 of the 112 patients 0.60-15.0 (median 5.49) years after initiating CRT. The observed incidence of SPC was 1.8 per 100 patient-years. Although trimodal therapy can prolong patient survival, the estimated incidence of SPC does not increase. A large prospective study with a longer follow-up time is required to determine the effects of trimodal therapy, including the development of SPC.",
keywords = "Cancer survivor, Chemoradiotherapy, Non-small-cell lung cancer, Second primary cancer, Surgical resection",
author = "Go Makimoto and Toshio Kubo and Isao Oze and Kadoaki Oohashi and Katsuyuki Hotta and Masahiro Tabata and Junichi Sou and Shinichi Toyooka and Kuniaki Katsui and Nagio Takigawa and Mitsune Tanimoto and Katsuyuki Kiura",
year = "2018",
month = "3",
day = "1",
doi = "10.1093/jjco/hyy003",
language = "English",
volume = "48",
pages = "287--290",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery

AU - Makimoto, Go

AU - Kubo, Toshio

AU - Oze, Isao

AU - Oohashi, Kadoaki

AU - Hotta, Katsuyuki

AU - Tabata, Masahiro

AU - Sou, Junichi

AU - Toyooka, Shinichi

AU - Katsui, Kuniaki

AU - Takigawa, Nagio

AU - Tanimoto, Mitsune

AU - Kiura, Katsuyuki

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The standard treatment for patients with locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT), but surgical resection following induction CRT can extend overall survival in a select population. However, patients who survive longer are at risk of developing a second primary cancer (SPC). This is the first report to determine the incidence of SPC in survivors with LA-NSCLC after trimodal therapy. Between October 1997 and October 2013, 112 Stage III NSCLC patients underwent trimodal therapy in our hospital. The 5-year overall survival rate was 71.8%. SPC developed in 10 of the 112 patients 0.60-15.0 (median 5.49) years after initiating CRT. The observed incidence of SPC was 1.8 per 100 patient-years. Although trimodal therapy can prolong patient survival, the estimated incidence of SPC does not increase. A large prospective study with a longer follow-up time is required to determine the effects of trimodal therapy, including the development of SPC.

AB - The standard treatment for patients with locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT), but surgical resection following induction CRT can extend overall survival in a select population. However, patients who survive longer are at risk of developing a second primary cancer (SPC). This is the first report to determine the incidence of SPC in survivors with LA-NSCLC after trimodal therapy. Between October 1997 and October 2013, 112 Stage III NSCLC patients underwent trimodal therapy in our hospital. The 5-year overall survival rate was 71.8%. SPC developed in 10 of the 112 patients 0.60-15.0 (median 5.49) years after initiating CRT. The observed incidence of SPC was 1.8 per 100 patient-years. Although trimodal therapy can prolong patient survival, the estimated incidence of SPC does not increase. A large prospective study with a longer follow-up time is required to determine the effects of trimodal therapy, including the development of SPC.

KW - Cancer survivor

KW - Chemoradiotherapy

KW - Non-small-cell lung cancer

KW - Second primary cancer

KW - Surgical resection

UR - http://www.scopus.com/inward/record.url?scp=85043472546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043472546&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyy003

DO - 10.1093/jjco/hyy003

M3 - Article

VL - 48

SP - 287

EP - 290

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 3

ER -